10x Genomics (TXG) Cash from Investing Activities (2018 - 2026)

10x Genomics' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$1.3 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 30.74% year-over-year to -$1.3 million; the TTM figure through Mar 2026 stood at -$12.9 million (up 71.53% YoY), while the FY2025 annual figure was -$13.4 million, up 58.82% from the prior year.
• Cash from Investing Activities came in at -$1.3 million for Q1 2026 at 10x Genomics, up from -$1.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $120.0 million in Q1 2023 to a low of -$257.6 million in Q1 2022.
• A 5-year average of -$15.6 million and a median of -$1.9 million in 2025 frame the typical range for Cash from Investing Activities.
• On a YoY basis, Cash from Investing Activities climbed as much as 367.75% in 2024 and fell as far as 493.89% in 2024.
• 10x Genomics' Cash from Investing Activities stood at -$33.2 million in 2022, then surged by 139.49% to $13.1 million in 2023, then plunged by 493.89% to -$51.6 million in 2024, then jumped by 96.5% to -$1.8 million in 2025, then increased by 27.37% to -$1.3 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$1.3 million, -$1.8 million, and -$8.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison